M
Mansour Alfayez
Researcher at University of Texas MD Anderson Cancer Center
Publications - 58
Citations - 1159
Mansour Alfayez is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 14, co-authored 46 publications receiving 714 citations. Previous affiliations of Mansour Alfayez include Tufts University.
Papers
More filters
Journal ArticleDOI
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
Naval Daver,Guillermo Garcia-Manero,Sreyashi Basu,Prajwal Boddu,Mansour Alfayez,Jorge E. Cortes,Marina Konopleva,Farhad Ravandi-Kashani,Elias Jabbour,Tapan M. Kadia,Graciela M. Nogueras-Gonzalez,Jing Ning,Naveen Pemmaraju,Courtney D. DiNardo,Michael Andreeff,Sherry Pierce,Tauna Gordon,Steven M. Kornblau,Wilmer Flores,Zainab Al-Hamal,Carlos E. Bueso-Ramos,Jeffrey L. Jorgensen,Keyur P. Patel,Jorge Blando,James P. Allison,Padmanee Sharma,Hagop M. Kantarjian +26 more
TL;DR: Azacitidine in combination with nivolumab therapy produced an encouraging response rate and overall survival in patients with R/R AML, particularly in HMA-naïve and salvage 1 patients.
Journal ArticleDOI
Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.
Ioannis Koulouridis,Mansour Alfayez,Thomas A Trikalinos,Thomas A Trikalinos,Ethan M Balk,Bertrand L. Jaber +5 more
TL;DR: In patients with CKD, higher ESA dose might be associated with all-cause mortality and cardiovascular complications independent of hemoglobin level, and use of epoetin alfa-equivalent doses is recommended.
Journal ArticleDOI
Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia
Jessica Galloway-Peña,Yushu Shi,Christine B. Peterson,Pranoti Sahasrabhojane,Vancheswaran Gopalakrishnan,Chelcy E Brumlow,Naval Daver,Mansour Alfayez,Prajwal C. Boddu,Abdul Wadud Khan,Jennifer A. Wargo,Kim Anh Do,Robert R. Jenq,Dimitrios P. Kontoyiannis,Samuel A. Shelburne +14 more
TL;DR: It is suggested that gut microbiome evaluation could assist with infectious risk stratification and that improved targeting of antibiotic administration during IC could decrease subsequent infectious complications of AML patients.
Journal ArticleDOI
CPX-351 (vyxeos) in AML
TL;DR: CPX-351 had a higher median OS than 7 + 3 in patients 60–75 years old with newly diagnosed AML-MRC or t-AML, and limitations and future directions with CPX- 351 use in AML are discussed.
Journal ArticleDOI
Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: a nested case-control study.
Ioannis Koulouridis,Mansour Alfayez,Hocine Tighiouart,Nicolaos E. Madias,David M. Kent,Jessica K. Paulus,Jessica K. Paulus,Bertrand L. Jaber +7 more
TL;DR: In a hospital-based adult population, out-of-hospital PPI use is not associated with hypomagnesemia at the time of hospital admission to medical services, and prospective cohort studies are needed to address this rare potential medication-related adverse effect.